Meeting
2014 ASCO Annual Meeting
Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry.
Authors
Gregory A. Daniels
UC San Diego Moores Cancer Center, La Jolla, CA
Gregory A. Daniels , Michael Morse , Michael K.K. Wong , Howard Kaufman , David F. McDermott , Sandra Aung , James N. Lowder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9054)
DOI
10.1200/jco.2014.32.15_suppl.9054
Abstract #
9054
Poster Bd #
258
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
First Author: Rongsu Qi
Poster
2023 ASCO Annual Meeting
A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.
First Author: Suzanne Phillips
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
The outcome and toxicity profile of checkpoint inhibitor immunotherapy subsequent to high-dose IL-2 in the treatment of metastatic melanoma and renal cell carcinoma.
First Author: Stephanie A. Berg
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Immunomodulation of pembrolizumab (pembro) treated metastatic melanoma patients (pts) after progression with sequential temozolomide (TMZ): A case series.
First Author: Umang Swami